<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656136</url>
  </required_header>
  <id_info>
    <org_study_id>1200.23</org_study_id>
    <secondary_id>2007-005983-28</secondary_id>
    <nct_id>NCT00656136</nct_id>
  </id_info>
  <brief_title>BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)</brief_title>
  <official_title>Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients
      with NSCLC who have received previous treatment with at least one but not more than two lines
      of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either
      gefitinib or erlotinib for a period of at least 12 weeks and then progressed.

      The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a
      single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population.
      Patients on both treatment arms will receive best supportive care in addition to study
      treatment.

      Patients enrolled into the trial will be treated and followed until death or lost to
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until death or the last patient out date, an average of 12 months</time_frame>
    <description>Overall survival was the duration from the date of randomization to the date of death. Patients who were alive were censored at the last contact date prior to the database lock.
For the primary analysis 11 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Primary analysis data cut-off date was 08 July 2010.
For the final analysis 13 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Final analysis data cut-off date was 04 October 2013.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months</time_frame>
    <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (OR)</measure>
    <time_frame>From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months</time_frame>
    <description>OR is defined as complete response (CR) and partial response (PR). Assessed by central independent review according to RECIST 1.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">585</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBW 2992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BIBW 2992 tablets once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients receive placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <description>Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.</description>
    <arm_group_label>BIBW 2992</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with pathologic confirmation of NSCLC Stage III-B (with pleural effusion) or
             Stage IV adenocarcinoma who have failed at least one but not more than two lines of
             cytotoxic chemotherapy (including adjuvant chemotherapy). One of the chemotherapy
             regimens must have been platinum-based.

          2. Progressive disease following at least 12 weeks of treatment with erlotinib (Tarceva®)
             or gefitinib (Iressa®)

          3. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2

          4. Patients with at least one tumor lesion that can accurately be measured by magnetic
             resonance imaging (MRI), or computed tomography (CT) in at least one dimension with
             longest diameter to be recorded as &gt;20 mm using conventional techniques or &gt;10 mm with
             spiral CT scan

          5. Male and female patients age &gt;18 years

          6. Life expectancy of at least three (3) months

          7. Written informed consent that is consistent with ICH-GCP guidelines

        Exclusion criteria:

          1. Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of treatment Day 1

          2. Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance
             non-cancer therapy) or immunotherapy within the past 4 weeks

          3. Active brain metastases

          4. Significant or recent acute gastrointestinal disorders with diarrhea

          5. Patients who have any other life-threatening illness or organ system dysfunction,

          6. Other malignancies diagnosed within the past five (5) years

          7. Radiotherapy within the past 2 weeks prior to treatment

          8. History of clinically significant or uncontrolled cardiac disease

          9. Adequate ANC and platelet count

         10. Adequate liver and kidney function

         11. Patients with any serious active infection including known HIV, active hepatitis B or
             active hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.23.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingman</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.1005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.1009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besançon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Besançon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon Cedex 4</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3306C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49010 Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49002 Innere Klinik und Poliklinik (Tumorforschung)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49003 Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49005 Krankenhaus Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49008 Universitätsklinik Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49004 Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49001 Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.49006 HSK, Dr. Horst-Schmidt-Kliniken GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.85202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orbassano (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cruces</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88604 Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88605 China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88606 National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88601 National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88602 Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88607 Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.88603 Chang Gung Memorial Hosp-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiangmai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.66003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pathumwan, Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.66002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Songkla</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.4403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.23.4406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Information</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>November 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2013</results_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two-arm, randomised (2:1 ratio), double-blind , placebo-controlled, multi-centre trial. 585 patients were randomised. All patients randomized received at least one dose of study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Plus Best Supportive Care (BSC)</title>
          <description>Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm.</description>
        </group>
        <group group_id="P2">
          <title>Afatinib 50 mg/Day Plus Best Supportive Care (BSC)</title>
          <description>Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus Best Supportive Care (BSC) or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195">Randomised patients.</participants>
                <participants group_id="P2" count="390">Randomised patients.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="390"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="322"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refused to take study medication</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown and others</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set (RS) included all patients randomised to receive treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Plus Best Supportive Care (BSC)</title>
          <description>Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm.</description>
        </group>
        <group group_id="B2">
          <title>Afatinib 50 mg/Day Plus Best Supportive Care (BSC)</title>
          <description>Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus BSC or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="390"/>
            <count group_id="B3" value="585"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="10.4"/>
                    <measurement group_id="B2" value="58" spread="10.8"/>
                    <measurement group_id="B3" value="58" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Eastern Cooperative Oncology Group (ECOG) performance score</title>
          <description>ECOG Performance Score was measured on 6 point scale where 0=&quot;Fully active&quot;, 1=&quot;Restricted in physically strenuous activity&quot; and 2=&quot;Ambulatory and capable of all self care but unable to carry out any work activities&quot;, 3=&quot;Capable of only limited self care, confined to bed or chair 50% or more of waking hours&quot;, 4=&quot;Bedbound&quot;, and 5=&quot;Death&quot;.</description>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG score = 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG score = 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG score = 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival was the duration from the date of randomization to the date of death. Patients who were alive were censored at the last contact date prior to the database lock.
For the primary analysis 11 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Primary analysis data cut-off date was 08 July 2010.
For the final analysis 13 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Final analysis data cut-off date was 04 October 2013.</description>
        <time_frame>From randomization until death or the last patient out date, an average of 12 months</time_frame>
        <population>Randomized set was all patients who were randomized and for this study all of these patients received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Best Supportive Care (BSC)</title>
            <description>Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib 50 mg/Day Plus Best Supportive Care (BSC)</title>
            <description>Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus BSC or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was the duration from the date of randomization to the date of death. Patients who were alive were censored at the last contact date prior to the database lock.
For the primary analysis 11 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Primary analysis data cut-off date was 08 July 2010.
For the final analysis 13 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Final analysis data cut-off date was 04 October 2013.</description>
          <population>Randomized set was all patients who were randomized and for this study all of these patients received at least one dose of study medication.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary analysis (358 deaths)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.96" lower_limit="10.15" upper_limit="14.26"/>
                    <measurement group_id="O2" value="10.78" lower_limit="9.95" upper_limit="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final analysis (526 deaths)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.73" lower_limit="10.05" upper_limit="14.06"/>
                    <measurement group_id="O2" value="10.87" lower_limit="9.95" upper_limit="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary analysis was performed after 358 deaths were observed among randomized patients. The data cut-off date for the primary analysis was 08 July 2010.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7428</p_value>
            <p_value_desc>P-value is one-sided (afatinib vs placebo) log rank test stratified by gender and baseline ECOG score (0,1 vs 2)</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model stratified by gender and baseline ECOG score (0,1 vs 2)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.077</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.862</ci_lower_limit>
            <ci_upper_limit>1.346</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final analysis was performed after 526 deaths were observed among randomized patients. The data cut-off date for the final analysis was 04 October 2013.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3955</p_value>
            <p_value_desc>P-value is one-sided (afatinib vs placebo) log rank test stratified by gender and baseline ECOG score (0,1 vs 2)</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model stratified by gender and baseline ECOG score (0,1 vs 2)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.976</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.814</ci_lower_limit>
            <ci_upper_limit>1.170</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).</description>
        <time_frame>From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months</time_frame>
        <population>Randomized set was all patients who were randomized and for this study all of these patients received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Best Supportive Care (BSC)</title>
            <description>Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib 50 mg/Day Plus Best Supportive Care (BSC)</title>
            <description>Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus BSC or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).</description>
          <population>Randomized set was all patients who were randomized and for this study all of these patients received at least one dose of study medication.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.95" upper_limit="1.68"/>
                    <measurement group_id="O2" value="3.29" lower_limit="2.79" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is one-sided (afatinib vs placebo) log rank test stratified by gender and baseline ECOG score (0,1 vs 2)</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Model stratified by gender and baseline ECOG score (0,1 vs 2)</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.381</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.306</ci_lower_limit>
            <ci_upper_limit>0.475</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (OR)</title>
        <description>OR is defined as complete response (CR) and partial response (PR). Assessed by central independent review according to RECIST 1.0.</description>
        <time_frame>From randomization to disease progression, death or the data cutoff on 07 July 2010, an average of 3.3 months</time_frame>
        <population>Randomized set was all patients who were randomized and for this study all of these patients received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Best Supportive Care (BSC)</title>
            <description>Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm.</description>
          </group>
          <group group_id="O2">
            <title>Afatinib 50 mg/Day Plus Best Supportive Care (BSC)</title>
            <description>Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus BSC or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (OR)</title>
          <description>OR is defined as complete response (CR) and partial response (PR). Assessed by central independent review according to RECIST 1.0.</description>
          <population>Randomized set was all patients who were randomized and for this study all of these patients received at least one dose of study medication.</population>
          <units>Percentage of patients with OR</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O2" value="7.4" lower_limit="5.0" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <p_value_desc>P-value is derived from logistic regression model adjusted for stratification factors, gender and baseline ECOG score (0, 1 vs 2)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Model stratified by gender and baseline ECOG score (0,1 vs 2)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>15.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>115</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of first drug intake up to 28 days after the last drug intake for on-treatment adverse events or the last patient out date on 4 October 2013.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients received matching placebo for 50 mg, 40 mg or 30 mg afatinib tablets starting with 50 mg/day. Dose reductions were managed in the same way as for the afatinib arm.</description>
        </group>
        <group group_id="E2">
          <title>Afatinib 50 mg/Day</title>
          <description>Patients started with a 50 mg/day dose. Dose reductions were permitted by the protocol to 40 mg/day plus BSC or 30 mg /day plus BSC based upon prespecified Adverse Events and Common Terminology Criteria for Adverse Events (CTCAE) grade (Version 3.0).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Eye movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="383" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="334" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

